Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€33.28

€33.28

11.280%
3.35
11.280%
€52.03
 
01.03.24 / Tradegate WKN: A2AGYB / Symbol: ARWR / Name: Arrowhead Pharma / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Arrowhead Pharmaceuticals Inc. Stock

A very strong showing by Arrowhead Pharmaceuticals Inc. today, with an increase of €3.35 (11.280%) compared to yesterday's price.
We see a rather positive sentiment for Arrowhead Pharmaceuticals Inc. with 13 Buy predictions and 2 Sell predictions.
With a target price of 52 € there is a hugely positive potential of 56.25% for Arrowhead Pharmaceuticals Inc. compared to the current price of 33.28 €.
So far the community has only identified positive things for Arrowhead Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Arrowhead Pharmaceuticals Inc. in the next few years

Pros
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Arrowhead Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Arrowhead Pharmaceuticals Inc. 11.280% 13.973% 12.470% 9.008% 18.182% -52.122% 86.966%
Ironwood Pharmaceuticals -4.570% -39.130% -36.364% -21.334% -19.231% 5.000% -32.961%
Novocure Ltd 4.440% 6.833% 11.391% -78.995% 5.149% -88.130% -
Iovance Biotherapeutics Inc. 6.630% 6.314% 109.042% 126.164% 98.386% -52.702% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-25

Arrowhead Pharma (ARWR) is a company within the Biotechnology and Medical Research industry, focusing on the development of therapeutic solutions. At first glance, the financials of the company seem to indicate some potential areas of concern, alongside some positive achievements. To gain a deeper understanding of the company's financial health and make an informed assessment, it is essential to delve into the details and identify the pros and cons of its financial performance.

Growing Revenue: Arrowhead Pharma has demonstrated a consistent growth in revenue over the years. In 2020, the total revenue was $87,992,066, which increased to $138,287,000 in 2021 and $243,231,000 in 2022. A growing revenue stream reflects positively on the company's business strategies and market presence.

Robust Research & Development (R&D) Investments: The company has consistently increased its investment in R&D, highlighting its commitment to innovation, a crucial factor for success in the biotechnology and medical research industry. In 2020, R&D expenses were $128,874,979, followed by an increase to $206,342,000 in 2021 and further to $297,307,000 in 2022.

Comments

Prediction Buy
Perf. (%) 16.32%
Target price 83.484
Change
Ends at 08.02.25

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 13.20%
Target price 46.440
Change
Ends at 07.02.25

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $50.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 4.20%
Target price 45.915
Change
Ends at 16.01.25

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $50.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Show more